Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
4-amino-2-trifluoromethyl-phenyl retinate
- Development stage
- Preclinical
- Lead developer
- Anhui Medical University
- Modality
- Small Molecules
01
Overview
4-amino-2-trifluoromethyl-phenyl retinate (ATPR) is a synthetic derivative of all-trans retinoic acid (ATRA) designed to possess superior anticancer properties compared to ATRA. ATPR inhibits proliferation and promotes differentiation of acute myeloid leukaemia (AML) cells. Its mechanism involves modulation of the RARα/LDHB/ERK-glycolysis signaling axis, with a dependency on retinoic acid receptor alpha (RARα) activity and effects on glycolytic metabolism via lactate dehydrogenase B (LDHB). The compound has also demonstrated anticancer activity in models of gastric, hepatic, and breast cancer. ATPR was designed and synthesized by a team at Anhui Medical University.
- Other names
- 4-amino-2-trifluoromethyl-phenyl retinate
02
Targets
RARA (Retinoic acid receptor alpha)CRABP2 (Cellular retinoic acid-binding protein 2)ERKFABP5 (Fatty acid-binding protein 5)
Beyond the preview
Go deeper on 4-amino-2-trifluoromethyl-phenyl retinate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 4-amino-2-trifluoromethyl-phenyl retinate.